Trial Profile
A Long-Term Clinical Study of TS-071 as Combination Therapy in Patients With Type 2 Diabetes on insulin therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2019
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 Jun 2016 New trial record